Stoke Therapeutics Inc
STOK31.920USD
-0.250-0.78%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.76BMarket Cap
44.97P/E TTM
More Details of Stoke Therapeutics Inc Company
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Stoke Therapeutics Inc Info
Ticker SymbolSTOK
Company nameStoke Therapeutics Inc
IPO dateJun 19, 2019
CEOSmith (Ian F)
Number of employees128
Security typeOrdinary Share
Fiscal year-endJun 19
Address45 Wiggins Avenue
CityBEDFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01730
Phone17814308200
Websitehttps://www.stoketherapeutics.com/
Ticker SymbolSTOK
IPO dateJun 19, 2019
CEOSmith (Ian F)
Company Executives of Stoke Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
323.77K
-20.00%
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
44.81K
-8.79%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
4.32K
--
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
Mr. Thomas Leggett
Mr. Thomas Leggett
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Seth L. Harrison, M.D.
Dr. Seth L. Harrison, M.D.
Independent Director
Independent Director
--
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Prof. Dr. Adrian R. Krainer, Ph.D.
Prof. Dr. Adrian R. Krainer, Ph.D.
Independent Director
Independent Director
323.77K
-20.00%
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Director
Director
44.81K
-8.79%
Mr. Jonathan Allan, J.D.
Mr. Jonathan Allan, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
4.32K
--
Dr. Barry S. Ticho, M.D., Ph.D.
Dr. Barry S. Ticho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Arthur A. Levin, Ph.D.
Dr. Arthur A. Levin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
13.82M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 24
Updated: Mon, Nov 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.37%
Lynx1 Capital Advisors LLC
9.46%
RTW Investments L.P.
8.97%
Baker Bros. Advisors LP
8.11%
Redmile Group, LLC
7.31%
Other
55.77%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.37%
Lynx1 Capital Advisors LLC
9.46%
RTW Investments L.P.
8.97%
Baker Bros. Advisors LP
8.11%
Redmile Group, LLC
7.31%
Other
55.77%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.92%
Investment Advisor/Hedge Fund
36.52%
Hedge Fund
18.10%
Research Firm
13.99%
Holding Company
5.56%
Individual Investor
4.08%
Bank and Trust
0.23%
Pension Fund
0.17%
Insurance Company
0.03%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
305
65.94M
115.45%
-1.62M
2025Q2
300
63.05M
115.48%
-5.58M
2025Q1
306
66.97M
122.66%
-2.21M
2024Q4
301
61.22M
115.58%
-8.44M
2024Q3
297
61.15M
115.51%
-9.18M
2024Q2
284
64.23M
122.75%
+5.19M
2024Q1
273
57.18M
122.36%
+3.72M
2023Q4
261
48.04M
104.80%
-6.40M
2023Q3
264
46.81M
105.69%
-6.29M
2023Q2
260
49.41M
111.78%
-2.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.95M
10.86%
+3.48M
+140.94%
Jun 30, 2025
Lynx1 Capital Advisors LLC
5.40M
9.86%
+112.75K
+2.13%
Jun 30, 2025
RTW Investments L.P.
5.12M
9.35%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
4.63M
8.46%
--
--
Jun 30, 2025
Redmile Group, LLC
4.38M
7.99%
-110.05K
-2.45%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
6.16%
+157.85K
+4.91%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.98M
5.44%
+148.82K
+5.26%
Jun 30, 2025
TD Securities, Inc.
3.17M
5.79%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.94M
5.36%
+162.06K
+5.84%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Innovator IBD 50 Fund ETF
3.41%
WisdomTree BioRevolution Fund
2.6%
First Trust Dow Jones Select MicroCap Index Fund
2.28%
Janus Henderson Small Cap Growth Alpha ETF
1.86%
Virtus LifeSci Biotech Clinical Trials ETF
1.72%
Global X Genomics & Biotechnology ETF
1.41%
Franklin Genomic Advancements ETF
1.05%
Invesco Dorsey Wright Healthcare Momentum ETF
0.91%
iShares Health Innovation Active ETF
0.74%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.73%
View more
Innovator IBD 50 Fund ETF
Proportion3.41%
WisdomTree BioRevolution Fund
Proportion2.6%
First Trust Dow Jones Select MicroCap Index Fund
Proportion2.28%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.86%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.72%
Global X Genomics & Biotechnology ETF
Proportion1.41%
Franklin Genomic Advancements ETF
Proportion1.05%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0.91%
iShares Health Innovation Active ETF
Proportion0.74%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.73%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Stoke Therapeutics Inc?
The top five shareholders of Stoke Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 5.95M shares, accounting for 10.86% of the total shares.
Lynx1 Capital Advisors LLC holds 5.40M shares, accounting for 9.86% of the total shares.
RTW Investments L.P. holds 5.12M shares, accounting for 9.35% of the total shares.
Baker Bros. Advisors LP holds 4.63M shares, accounting for 8.46% of the total shares.
Redmile Group, LLC holds 4.38M shares, accounting for 7.99% of the total shares.
Fidelity Management & Research Company LLC holds 5.95M shares, accounting for 10.86% of the total shares.
Lynx1 Capital Advisors LLC holds 5.40M shares, accounting for 9.86% of the total shares.
RTW Investments L.P. holds 5.12M shares, accounting for 9.35% of the total shares.
Baker Bros. Advisors LP holds 4.63M shares, accounting for 8.46% of the total shares.
Redmile Group, LLC holds 4.38M shares, accounting for 7.99% of the total shares.
What are the top three shareholder types of Stoke Therapeutics Inc?
The top three shareholder types of Stoke Therapeutics Inc are:
Fidelity Management & Research Company LLC
Lynx1 Capital Advisors LLC
RTW Investments L.P.
Fidelity Management & Research Company LLC
Lynx1 Capital Advisors LLC
RTW Investments L.P.
How many institutions hold shares of Stoke Therapeutics Inc (STOK)?
As of 2025Q3, 305 institutions hold shares of Stoke Therapeutics Inc, with a combined market value of approximately 65.94M, accounting for 115.45% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.03%.
What is the biggest source of revenue for Stoke Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Stoke Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
